secwatch.observer — SEC 8-K summary
======================================

Issuer:     CORCEPT THERAPEUTICS INC (CORT)
CIK:        0001088856
Form:       8-K
Filed at:   2025-02-26T23:59:59+00:00
Accession:  0001628280-25-008131
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Corcept Q4/FY2024: Revenue $675M (+40%), Net Income $141M; Guides 2025 $900-950M
--------------------------------------------------------------------------------

- Q4 revenue $181.9M vs $135.4M YoY; FY revenue $675.0M (+40% YoY).
- FY net income $141.2M ($1.23 diluted EPS) vs $106.1M ($0.94) in 2023.
- 2025 revenue guidance $900-$950M; cash and investments $603.2M at Dec 31, 2024.
- NDA submitted for relacorilant for hypercortisolism; ROSELLA Phase 3 data expected this quarter.
- DAZALS Phase 2 in ALS missed primary endpoint; showed survival benefit (0 vs 5 deaths at 24 weeks, p=0.02).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1088856/000162828025008131/0001628280-25-008131-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1088856/000162828025008131/cort-20250226.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-008131

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer